NCI-H929

NCI-H929 (Multiple Myeloma CDX Model) 

The NCI-H929 line was derived from a patient with multiple myeloma. It represents plasma cell malignancies and secretes immunoglobulin. NCI-H929 is widely used in drug testing and biomarker research. Its reproducibility makes it a standard in translational hematology. 

Key Features: 

• Derived from multiple myeloma. 

• Produces immunoglobulin. 

• B-cell plasma phenotype. 

• Tumorigenic in xenografts. 

Applications: 
NCI-H929 supports evaluation of novel therapeutics for multiple myeloma. Researchers use it in biomarker and resistance studies. It is also applied in drug discovery targeting malignant plasma cells. Its reproducibility ensures reliability in hematology pipelines.